ME02352B - PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA - Google Patents

PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA

Info

Publication number: ME02352B
Authority: ME; Montenegro
Prior art keywords: amyloid beta; beta peptide; peptide antibodies; n3pglu amyloid; n3pglu
Prior art date: 2010-08-12

Application number

MEP-2016-28A

Other languages

German (de)

English (en)

French (fr)

Inventor

Jirong Lu

Ying Tang

Ronald Bradley Demattos

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-12

Filing date

2011-08-09

Publication date

2016-06-20

2011-08-09 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2016-06-20 Publication of ME02352B publication Critical patent/ME02352B/me

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MEP-2016-28A 2010-08-12 2011-08-09 PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA ME02352B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US37302610P	2010-08-12	2010-08-12
PCT/US2011/046994 WO2012021469A1 (en)	2010-08-12	2011-08-09	ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
EP11745672.3A EP2603523B1 (en)	2010-08-12	2011-08-09	ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number	Publication Date
ME02352B true ME02352B (me)	2016-06-20

Family

ID=44543826

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
MEP-2019-356A ME03661B (me)	2010-08-12	2011-08-09	Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
MEP-2016-28A ME02352B (me)	2010-08-12	2011-08-09	PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
MEP-2018-79A ME03032B (me)	2010-08-12	2011-08-09	Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MEP-2019-356A ME03661B (me)	2010-08-12	2011-08-09	Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MEP-2018-79A ME03032B (me)	2010-08-12	2011-08-09	Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba

Country Status (38)

Country	Link
US (2)	US8679498B2 (me)
EP (3)	EP2603523B1 (me)
JP (2)	JP5980207B2 (me)
KR (1)	KR101498833B1 (me)
CN (2)	CN105111308B (me)
AU (1)	AU2011289629B2 (me)
BR (1)	BR112013004056B8 (me)
CA (1)	CA2805114C (me)
CL (1)	CL2013000390A1 (me)
CO (1)	CO6670526A2 (me)
CR (1)	CR20130016A (me)
CY (2)	CY1120144T1 (me)
DK (3)	DK2603523T3 (me)
DO (1)	DOP2013000029A (me)
EA (1)	EA023021B1 (me)
EC (1)	ECSP13012436A (me)
ES (3)	ES2564252T3 (me)
GT (1)	GT201300036A (me)
HK (1)	HK1180703A1 (me)
HR (3)	HRP20160151T1 (me)
HU (2)	HUE028678T2 (me)
IL (2)	IL224030B (me)
LT (2)	LT3042917T (me)
MA (1)	MA34461B1 (me)
ME (3)	ME03661B (me)
MX (2)	MX342782B (me)
MY (2)	MY181969A (me)
NO (1)	NO3042917T3 (me)
NZ (2)	NZ626665A (me)
PE (1)	PE20130817A1 (me)
PL (3)	PL3042917T3 (me)
PT (2)	PT3042917T (me)
RS (3)	RS59652B1 (me)
SG (2)	SG187586A1 (me)
SI (3)	SI3339323T1 (me)
UA (1)	UA107600C2 (me)
WO (1)	WO2012021469A1 (me)
ZA (1)	ZA201300437B (me)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL199534A (en)	2007-01-05	2013-01-31	Univ Zuerich	An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
PL3042917T3 (pl) *	2010-08-12	2018-07-31	Eli Lilly And Company	Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
US9499610B2 (en)	2011-04-08	2016-11-22	H. Lundbeck A/S	Antibodies specific to pyroglutamated Aβ
US20170008955A1 (en) *	2014-02-03	2017-01-12	Cnj Holdings, Inc.	Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en)	2014-05-15	2015-11-19	Biogen Ma Inc.	Methods for the detection of amyloid beta oligomers in biological samples
AU2015287227B2 (en)	2014-07-10	2021-02-18	Universitat Zurich	Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) *	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en)	2014-12-19	2017-12-21	Probiodrug Ag	Novel Method for the Detection of pGlu-Abeta Peptides
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
MY195059A (en) *	2015-09-23	2023-01-05	Regeneron Pharma	Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
IL260218B2 (en)	2016-01-11	2023-04-01	Novartis Ag	Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
JOP20170004B1 (ar) *	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740944A (zh)	2016-03-15	2017-12-01	美國禮來大藥廠	組合療法
TW201740954A (zh) *	2016-03-16	2017-12-01	美國禮來大藥廠	組合療法
TWI798751B (zh) *	2016-07-01	2023-04-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en)	2016-07-04	2018-07-31	H. Lundbeck A/S	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CA3032692A1 (en) *	2016-08-09	2018-02-15	Eli Lilly And Company	Combination antibody therapy for the treatment of neurodegenerative diseases
WO2018034977A1 (en)	2016-08-18	2018-02-22	Eli Lilly And Company	Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) *	2016-10-21	2019-08-21	美國禮來大藥廠	組合療法
BR112018013247A2 (pt)	2016-10-28	2018-12-04	H Lundbeck As	tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
EP3532053A1 (en)	2016-10-28	2019-09-04	H. Lundbeck A/S	Combination treatments comprising administration of imidazopyrazinones
TW201827467A (zh)	2016-11-03	2018-08-01	比利時商健生藥品公司	焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) *	2017-04-20	2019-10-20	Lilly Co Eli	أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CN111201037B (zh)	2017-08-22	2024-04-02	比奥根Ma公司	含有抗β淀粉样蛋白抗体的药物组合物
CA3085201A1 (en)	2017-12-14	2019-06-20	H. Lundbeck A/S	Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es)	2017-12-14	2020-07-01	H Lundbeck As	Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (en)	2017-12-20	2019-06-27	H. Lundbeck A/S	Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
US20220177560A1 (en) *	2019-03-26	2022-06-09	Janssen Pharmaceutica Nv	Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
JP7551744B2 (ja)	2019-10-15	2024-09-17	イーライリリーアンドカンパニー	組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
US20230250193A1 (en) *	2020-06-17	2023-08-10	Proviva Therapeutics (Hong Kong) Limited	Antibodies to fibroblast activation protein and b7h3
JP2023535024A (ja)	2020-07-23	2023-08-15	オタープロシーナリミテッド	抗ａベータ抗体
AU2021355521A1 (en)	2020-10-02	2023-05-11	Eli Lilly And Company	Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content
TWI843040B (zh)	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
KR20240099297A (ko)	2021-10-22	2024-06-28	일라이 릴리 앤드 캄파니	O-GlcNAcase (OGA) 억제제 조합 요법
MX2024005145A (es)	2021-10-29	2024-05-13	Lilly Co Eli	Compuestos y metodos dirigidos a la interleucina-34.
MX2024005146A (es)	2021-10-29	2024-05-13	Lilly Co Eli	Compuestos y metodos dirigidos a interleucina-34.
KR20240099347A (ko)	2021-10-29	2024-06-28	일라이 릴리 앤드 캄파니	인터류킨-34를 표적화하는 화합물 및 방법
WO2023076995A1 (en)	2021-10-29	2023-05-04	Eli Lilly And Company	Compounds and methods targeting interleukin-34
IL314657A (en)	2022-02-03	2024-09-01	Lilly Co Eli	TAU regional imaging for the diagnosis and treatment of Alzheimer's disease
WO2024020470A1 (en) *	2022-07-21	2024-01-25	Eli Lilly And Company	PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF
WO2024133925A1 (en)	2022-12-22	2024-06-27	Bioarctic Ab	Antibody which binds to abetape3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US7122374B1 (en) *	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
JP2006513259A (ja)	2002-07-24	2006-04-20	イノジェネティックス・ナムローゼ・フェンノートシャップ	ベータ−アミロイド生成および／または凝集に関連した疾病の防止、処置および診断
WO2005018424A2 (en) *	2003-08-18	2005-03-03	Research Foundation For Mental Hygiene, Inc.	Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EP1666061A1 (en)	2003-09-09	2006-06-07	Takeda Pharmaceutical Company Limited	Use of antibody
EA009872B1 (ru) *	2004-02-23	2008-04-28	Эли Лилли Энд Компани	АНТИ-Aβ АНТИТЕЛА
EP2298807A3 (en) *	2004-07-30	2011-05-18	Rinat Neuroscience Corp.	Antibodies directed against amyloid-beta peptide and methods using same
AU2007275467B2 (en)	2006-07-14	2013-12-05	Ac Immune S.A.	Humanized antibody against amyloid beta
AU2008242648B2 (en) *	2007-04-18	2013-09-12	Janssen Alzheimer Immunotherapy	Prevention and treatment of cerebral amyloid angiopathy
MX2010013647A (es)	2008-06-12	2011-04-05	Affiris Ag	Compuestos para tratar sintomas asociados con la enfermedad de parkinson.
WO2010004434A2 (en)	2008-07-09	2010-01-14	University Of Zurich	Method of promoting neurogenesis
CA2731044C (en)	2008-07-21	2020-07-14	Probiodrug Ag	Diagnostic antibody assay
EP2576617B1 (en)	2010-06-04	2016-04-27	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin	MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
PL3042917T3 (pl) *	2010-08-12	2018-07-31	Eli Lilly And Company	Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

2011
- 2011-08-09 PL PL15196358T patent/PL3042917T3/pl unknown
- 2011-08-09 MX MX2013001716A patent/MX342782B/es active IP Right Grant
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/me unknown
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/me unknown
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/lt unknown
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/es active Active
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 PT PT151963584T patent/PT3042917T/pt unknown
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 SI SI201131817T patent/SI3339323T1/sl unknown
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/lt unknown
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/zh active Active
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/me unknown
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/da active
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/ko active IP Right Grant
- 2011-08-09 SI SI201130740T patent/SI2603523T1/sl unknown
- 2011-08-09 ES ES18150424T patent/ES2764728T3/es active Active
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/hu unknown
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/zh active Active
- 2011-08-09 EA EA201270813A patent/EA023021B1/ru not_active IP Right Cessation
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/es active Active
- 2011-08-09 PL PL18150424T patent/PL3339323T3/pl unknown
- 2011-08-09 PT PT181504242T patent/PT3339323T/pt unknown
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/ja active Active
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en active Application Filing
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/pt active IP Right Grant
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 RS RS20191581A patent/RS59652B1/sr unknown
- 2011-08-09 RS RS20160129A patent/RS54685B1/en unknown
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/es active IP Right Grant
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 RS RS20180323A patent/RS57026B1/sr unknown
- 2011-08-09 MA MA35653A patent/MA34461B1/fr unknown
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 PL PL11745672T patent/PL2603523T3/pl unknown
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-09-08 UA UAA201301508A patent/UA107600C2/ru unknown
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
2013
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-01-16 CR CR20130016A patent/CR20130016A/es unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/es unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/es unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/es unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/es unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/es unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/es unknown
- 2013-07-11 HK HK13108135.4A patent/HK1180703A1/zh unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
2016
- 2016-02-10 HR HRP20160151TT patent/HRP20160151T1/hr unknown
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/ja active Active
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/hr unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/el unknown
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/hr unknown
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/el unknown
2021
- 2021-07-29 IL IL285226A patent/IL285226B2/en unknown

Also Published As

Publication number	Publication date
AU2011289629B2 (en)	2014-07-03
HK1180703A1 (zh)	2013-10-25
AU2011289629A1 (en)	2013-02-14
RS54685B1 (en)	2016-08-31
IL224030B (en)	2022-04-01
IL285226B (en)	2022-10-01
SG10201509330XA (en)	2015-12-30
CN105111308A (zh)	2015-12-02
MA34461B1 (fr)	2013-08-01
US8679498B2 (en)	2014-03-25
SI3339323T1 (sl)	2019-12-31
EP2603523B1 (en)	2016-01-27
PL3339323T3 (pl)	2020-05-18
DK3339323T3 (da)	2020-01-20
EA023021B1 (ru)	2016-04-29
MY181969A (en)	2021-01-15
ES2564252T3 (es)	2016-03-21
EP3339323A1 (en)	2018-06-27
MY163521A (en)	2017-09-15
EA201270813A1 (ru)	2013-05-30
PE20130817A1 (es)	2013-07-18
PL2603523T3 (pl)	2016-07-29
HRP20180616T1 (hr)	2018-07-13
SI3042917T1 (en)	2018-04-30
UA107600C2 (uk)	2015-01-26
RS59652B1 (sr)	2020-01-31
KR20130051989A (ko)	2013-05-21
CN103068848A (zh)	2013-04-24
PL3042917T3 (pl)	2018-07-31
NZ626665A (en)	2016-04-29
DK2603523T3 (en)	2016-03-21
CN105111308B (zh)	2019-03-12
KR101498833B1 (ko)	2015-03-04
SG187586A1 (en)	2013-03-28
CR20130016A (es)	2013-03-21
GT201300036A (es)	2014-07-16
JP2013536191A (ja)	2013-09-19
CY1120144T1 (el)	2018-12-12
HRP20192233T1 (hr)	2020-03-06
WO2012021469A1 (en)	2012-02-16
NO3042917T3 (me)	2018-07-21
LT3339323T (lt)	2020-02-10
CA2805114C (en)	2017-12-05
CN103068848B (zh)	2015-11-25
ME03032B (me)	2018-10-20
JP5980207B2 (ja)	2016-08-31
US20130142806A1 (en)	2013-06-06
CA2805114A1 (en)	2012-02-16
CY1122458T1 (el)	2021-01-27
SI2603523T1 (sl)	2016-04-29
EP3042917B1 (en)	2018-02-21
ME03661B (me)	2020-07-20
ZA201300437B (en)	2014-06-25
EP3042917A1 (en)	2016-07-13
BR112013004056A2 (pt)	2020-08-04
HUE028678T2 (en)	2016-12-28
JP2016179985A (ja)	2016-10-13
US20140065138A1 (en)	2014-03-06
PT3339323T (pt)	2020-01-14
LT3042917T (lt)	2018-05-10
NZ606095A (en)	2014-11-28
RS57026B1 (sr)	2018-05-31
DK3042917T3 (en)	2018-04-23
IL285226A (en)	2021-09-30
MX355268B (es)	2018-04-11
BR112013004056B8 (pt)	2022-10-18
BR112013004056B1 (pt)	2022-05-17
EP3339323B1 (en)	2019-11-13
DOP2013000029A (es)	2013-03-15
HRP20160151T1 (hr)	2016-03-11
MX2013001716A (es)	2013-10-28
HUE037524T2 (hu)	2018-09-28
MX342782B (es)	2016-10-12
JP6395755B2 (ja)	2018-09-26
PT3042917T (pt)	2018-05-02
CO6670526A2 (es)	2013-05-15
US8961972B2 (en)	2015-02-24
IL285226B2 (en)	2023-02-01
ES2664128T3 (es)	2018-04-18
CL2013000390A1 (es)	2014-03-21
EP2603523A1 (en)	2013-06-19
ECSP13012436A (es)	2013-03-28
ES2764728T3 (es)	2020-06-04

Publication	Publication Date	Title
IL285226A (en)	2021-09-30	Antibodies against amyloid beta peptide n3pglu and their uses
IL230918A0 (en)	2014-03-31	Modified proteins and peptides
HUE057004T2 (hu)	2022-04-28	CD277 elleni antitestek és alkalmazásaik
IL222961B (en)	2018-08-30	DNA binding proteins and their uses
HK1180601A1 (zh)	2013-10-25	抗體製劑
HK1179981A1 (zh)	2013-10-11	的抗體及其用途
ZA201206916B (en)	2014-03-26	Oligomer-specific amyloid beta epitope and antibodies
EP2593475A4 (en)	2014-03-05	ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
EP2632952A4 (en)	2014-04-30	ANTI-SOD1 ANTIBODIES AND USES THEREOF
PL2621955T3 (pl)	2018-07-31	Przeciwciała anty-CEACAM6 i ich zastosowania
HK1168622A1 (en)	2013-01-04	Antigen peptide and use thereof
EP2785738A4 (en)	2015-07-22	ANTI-NPY ANTI-PYY ANTIBODIES AND USES THEREOF
EP2771689A4 (en)	2015-06-03	PEPTIDES USP2A AND ANTIBODIES
EP2545378A4 (en)	2013-11-13	ANTI-LG3 ANTIBODIES AND USES THEREOF
GB201121236D0 (en)	2012-01-18	Proteins and peptides
GB201121233D0 (en)	2012-01-18	Modified proteins and peptides
GB201121226D0 (en)	2012-01-18	Modified proteins and peptides